Invision Medi Sciences

What Invision Medi Sciences does

Invision Medi Sciences Pvt. Ltd. is an India-based privately held pharmaceutical company founded in 2004 that manufactures and distributes generic formulations and nutritional supplements across more than fifteen therapeutic categories, including cardiac, diabetic, neurology, anti-inflammatory, gastro-hepatic, nephro-urology, gynaecology, dermatology, and immunity segments. Its product engineering centers on pharmaceutical formulation work — bi-layer tablet architectures for dual-release paracetamol, sustained-release (SR) dosage forms, novel triple-combination analgesics, and Ayurvedic herbomineral topical preparations — alongside conventional small-molecule generics and a catalog of 92+ nutritional supplements. The catalog is segmented across seven branded divisions (Botons & Blues, Respigeno, Ikeirdorf, Idalis, Intencis Derma, Infalife, MarxRemedies), each with its own digital identity.

The company's revenue model rests on two pillars. The primary pillar is a pharma franchise network across India, in which partners holding valid drug licenses and GST registrations receive exclusive territorial rights, marketing materials, training, and access to the full product portfolio; pricing is flexible by territory and undisclosed publicly. The secondary pillar is third-party / private-label manufacturing, which monetizes the company's formulation capacity by supplying other brands. All formulations are positioned as DCGI approved, and the company markets itself on 20+ years of operating history and a Quality Brand Award. The company does not sell direct-to-consumer and operates exclusively within India, with no disclosed revenue, headcount, funding, or M&A activity.

Name

Invision Medi Sciences

Legal name

Invision Medi Sciences Pvt. Ltd.

Website

https://invisionmedi.com

Company type

Private

Founded year

2004

Operating status

Operating

Headcount range

51–100 employees

Short description

Invision Medi Sciences is a privately held India-based pharmaceutical company founded in 2004 that manufactures generic formulations and nutritional supplements across 15+ therapeutic categories and distributes them through a nationwide pharma franchise and C&F agent network organized under seven branded divisions.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)

akta.pro secondary industries

Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE), Specialty Care Pharmaceuticals (HLAIAAAB), Specialty Pharma & Biologics Distribution (GDP-compliant) (HLAGAMAD)

Keywords

• Pharmaceutical manufacturing
• Pharma franchise
• Generic formulations
• Third-party manufacturing
• Cardiac diabetic range

Headquarters

HQ city

Bangalore

HQ country

India

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Operations, Technology or R&D, Marketing or Sales

Revenue model

1. Pharma Franchise Revenue: Invision Medi Sciences generates revenue by recruiting pharma franchise partners across India who distribute the company's pharmaceutical products in designated territories. Franchise partners pay for the rights to market and sell the company's product portfolio, which spans multiple therapeutic segments including cardiac, diabetes, neurology, anti-inflammatory, and nutritional supplements.
2. Private Label / Third-Party Manufacturing: The company offers private label and third-party manufacturing solutions, allowing other businesses to brand and distribute Invision's pharmaceutical formulations under their own labels.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Core offering

Invision Medi Sciences manufactures and distributes a broad portfolio of DCGI-approved pharmaceutical formulations (tablets, syrups, topical preparations) and nutritional supplements across 15+ therapeutic segments including cardiac, diabetic, neurology, anti-inflammatory, gastrology, hepatoprotective, nephro/urology, antibiotics, steroids, and nutrition supplements. The company monetizes this portfolio primarily through a pharma franchise model, granting exclusive territorial marketing rights to franchise partners in India, and supplements this with private label / third-party manufacturing services for other pharmaceutical brands.

Product overview

Invision Medi Sciences is a pharmaceutical company in India offering a diverse portfolio of generic pharmaceutical products and nutritional supplements through multiple therapeutic divisions. The company operates through seven branded divisions (Botons & Blues, Respigeno, Ikeirdorf, Idalis, Intencis Derma, Infalife, MarxRemedies) and provides pharma franchise opportunities. Key product categories include cardiac care (Rosact T, METOCARE, ACORD series), diabetes management (Linovio-M, Linovio-5, Linovio-D, GLITRAC-M, GLAMOR-PM, GLAMOR-1), anti-inflammatory/analgesics (Nurodon-LF, FENACE, FLUPICIN-P, STARCAM-MD, FLEXIGESIC), neurological supplements (Cobanerve-LC), and nutritional supplements. The company also manufactures products for hepatoprotective, nephro/urology, gynaecology, dental, gastrology, steroids, antibiotics, and immunity boosting segments.

Differentiator

Problem solved

Functional benefit

Brands

• Botons & Blues: One of the pharmaceutical product divisions of Invision Medi Sciences
• Respigeno
• Ikeirdorf
• Idalis
• Intencis Derma
• Infalife
• MarxRemedies

Products and services

• HEPABACT-550 Tablets Rifaximin 550mg tablet formulation for hepatoprotective / hepatic and digestive health applications, marketed as a first-to-market specialty molecule.
• URIFINE-B6 Syrup Syrup formulation for nephro/urology support, including kidney stone management and urinary tract health.
• FENACE-PLUS 650 Tablets Paracetamol 650mg tablet formulation for cold and flu symptom relief.
• COLDWAR-PLUS Tablets Multi-symptom relief tablet formulation for cold, cough, and allergies.
• Intriz-HDR 10 Pharmaceutical tablet product for healthcare applications.
• Intriz-HDR 25 Pharmaceutical tablet product for healthcare applications.
• Bilafast-DM Syrup Syrup formulation for digestive and hepatic support applications.
• Rosact T 10/40 Telmisartan 40mg + Rosuvastatin 10mg combination tablet for hypertension and hyperlipidemia management.
• Nurodon-LF 10 Leflunomide 10mg tablet, a DMARD for rheumatoid arthritis and psoriatic arthritis treatment.
• Nurodon-LF 20 Leflunomide 20mg tablet, a DMARD for rheumatoid arthritis and psoriatic arthritis treatment.
• Cobanerve-LC Tablets Neurological supplement containing Methylcobalamin, L-Carnitine L-Tartrate, and Folic Acid for nerve health and neuropathy support.
• Linovio-M 500 Linagliptin 2.5mg + Metformin HCL 500mg combination tablet for type 2 diabetes glycemic control.
• Linovio-M 1000 Linagliptin 2.5mg + Metformin HCL 1000mg combination tablet for type 2 diabetes glycemic control.
• Linovio-5 Linagliptin 5mg tablet, a DPP-4 inhibitor for type 2 diabetes management.
• Linovio-D Linagliptin 5mg + Dapagliflozin 10mg combination tablet for dual-action type 2 diabetes management.
• GLITRAC-M Glibenclamide 5mg + Metformin HCI 500mg combination tablet for type 2 diabetes management.
• GLAMOR-PM Glimepiride, Metformin, and Pioglitazone triple-combination tablet for type 2 diabetes therapy.
• GLAMOR-1 Glimepiride tablet for type 2 diabetes insulin secretion enhancement.
• METOCARE 25 & 50 Tablets Metoprolol Tartrate 25/50mg tablet, a beta-blocker for hypertension and angina treatment.
• Pharma Franchise Program Franchise partnership offering for entrepreneurs and pharma distributors in India. Partners must hold a valid drug license and GST registration, receive exclusive territorial marketing rights, comprehensive product supply, training, marketing materials, and promotional support across 15+ therapeutic segments.
• Private Label / Third-Party Manufacturing Contract manufacturing service allowing other pharmaceutical businesses to brand and distribute Invision's DCGI-approved pharmaceutical formulations under their own labels across multiple therapeutic segments.

Quantifiable outcome

• 20+ Years of pharmaceutical expertise in the Indian market
• +2 more outcomes

Named customers3 records

Segments15 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Cipla: One of India's largest pharmaceutical manufacturers with branded generics spanning respiratory, cardiac, anti-infectives, and other segments; competes with Invision across multiple therapeutic categories but at vastly larger scale.
• Alkem Laboratories: Leading Indian pharma manufacturer with an extensive branded generics footprint across multiple therapeutic segments and active third-party manufacturing services, comparable in scale and breadth to Invision's portfolio.
• Emcure Pharmaceuticals: Established Indian pharma company with broad therapeutic coverage and active franchise distribution in India, comparable in B2B franchise model to Invision.
• Lupin Limited: Major Indian pharma company with extensive domestic branded generics and franchise-like distribution; overlaps with Invision on cardiac, diabetic, and respiratory therapy areas.
• Glenmark Pharmaceuticals: Indian-headquartered multinational pharma company with branded formulations across cardiac, diabetic, derma, and respiratory—overlapping with Invision's primary therapeutic segments.
• Torrent Pharmaceuticals: Large Indian pharma manufacturer with significant presence in cardiac and diabetic segments—an area where Invision also positions primary franchises.
• Mankind Pharma: One of India's largest pharma companies with a deep PCD/franchise model across India, operating a broad branded generics portfolio in cardiac, diabetic, derma, and other therapeutic segments directly comparable to Invision's franchise positioning.

Direct peers

• Aristo Pharmaceuticals: Mid-sized Indian pharma firm known for its PCD franchise model offering branded generics across therapeutic areas like cardiac, anti-diabetic, and nutrition; matches Invision's franchise-distributed business model closely.
• Akums Drugs & Pharmaceuticals: India's largest contract development and manufacturing organization (CDMO) with strong third-party manufacturing—directly comparable to Invision's private label/third-party manufacturing revenue stream.
• Macleods Pharmaceuticals: Indian pharma company with multi-therapeutic segments and a strong PCD franchise network across India—directly comparable franchise/PCD model and product breadth to Invision Medi Sciences.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/invisionmediscience
• LinkedInlinkedin.com/company/invision-medi-sciences-pvt-ltd
• Instagraminstagram.com/invisionmedisciencepvtltd
• Xx.com/Invision___

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Invision Medi Sciences